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Abstract
Background: There are randomized trials assessing a variety of antiviral drugs for hepatitis B virus (HBV), but the
relative effectiveness of these drugs in the treatment of patients co-infected with human immunodeficiency virus
(HIV) remains unclear. The objectives of the current study were to estimate and rank the relative effectiveness of
antiviral drugs for treating HBV and HIV co-infected patients.
Methods: Randomized trials, assessing the efficacy of antiviral drugs for HBV and HIV co-infected patients were
searched in health-related databases. The methodological quality of the included trials was evaluated using the
Cochrane risk of bias tool. Main outcome in this meta-analysis study was the success of treatment by antivirals as
determined by virologic response. We performed pairwise and network meta-analysis of these trials and assessed
the quality of evidence using the GRADE approach.
Results: Seven randomized trials (329 participants) were included in this network meta-analysis study. A network
geometry was formed with six treatment options including four antiviral drugs, adefovir (ADV), emtricitabine (FTC),
lamivudine (LMV) and tenofovir disoproxil fumarate (TDF), combination treatment of TDF plus LMV, and placebo.
The weighted percentage contributions of each comparison distributed fairly equally in the entire network of
evidence. An assumption of consistency required for network meta-analysis was not violated (the global Wald test
for inconsistency: Chi2(4) = 3.63, p = 0.46). The results of estimates showed no differences between the treatment
regimens in terms of viral response for treating HBV and HIV co-infected patients, which spanned both benefit and
harm (e.g. LMV vs TDF plus LMV: OR: 0.37, 95%CI: 0.06–2.41). Overall, the certainty of evidence was very low in all
comparisons (e.g. LMV vs TDF plus LMV: 218 fewer per 1000,121 more to 602 fewer, very low certainty). Therefore,
we remained uncertain to the true ranking of the antiviral treatments in HBV/ HIV co-infected patients.
Conclusions: The findings suggest that the evidence is insufficient to provide guidance to the relative effectiveness of
currently available antiviral drugs with dual activity in treating co-infection of HBV/HIV. Well-designed, large clinical trials
in this field to address other important outcomes from different epidemiological settings are recommended.
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Background
Human immunodeficiency virus (HIV) is an RNA virus
and hepatitis B virus (HBV) is a partially double stranded
DNA virus, both of which share common modes of trans-
mission. Studies have reported that co-infection with HBV
and HIV-1 is common [1–3]. Among the 40 million per-
sons infected with HIV worldwide, an estimated 2–4 mil-
lion are co-infected with HBV [4], albeit with variation in
age-specific prevalence, geographic distribution and the
predominant routes of transmission [4, 5]. Hence, the treat-
ment of chronic HBV in HIV-infected individuals with dual
antiretroviral therapy (ART) requires careful consideration.
In co-infected patients, HIV accelerates the progres-
sion of HBV-related liver disease. It has been reported
that HIV infection has negative impact on the natural
history of HBV infection leading to increased rates of
persistent infection, higher HBV DNA levels, lower rates
of hepatitis Be antigen loss, increased cirrhosis and
liver-related mortality, and increased risk of hepatocellu-
lar carcinoma (HCC) at lower CD4+ T cell counts [6].
The aim of treating HBV infection is to prevent patients
from progressing to the chronic stage [7, 8].
Thus far, emtricitabine (FTC), lamivudine (LMV), tenofo-
vir disoproxil fumarate (TDF) and tenofovir alafenamide
(TAF) have demonstrated dual activity for HBV and HIV
[9]. However, these drugs vary in therapeutic activity and
toxicity. There are randomized trials (RCTs) assessing a var-
iety of antiviral drugs for HBV, but their relative effective-
ness in the treatment of patients co-infected with HBV and
HIV remains unclear. A network meta-analysis permits in-
ferences into the comparative effectiveness of interventions
from direct comparisons (i.e., treatments are directly com-
pared within an RCT) and indirect comparisons (i.e., treat-
ments are compared between RCTs by combining results
against a common comparator treatment) and it also allows
ranking of these different treatments [10, 11]. Overall, the
objectives of the current study were to estimate and rank
the relative effectiveness of antiviral drugs for treating HBV
and HIV co-infected patients.
Methods
The current study was performed in accordance with
the preferred reporting items for network meta-analyses
(PRISMA-NMA) [12]. A protocol of this study is avail-
able in PROSPERO (CRD42016035539).
Search
Relevant RCTs were searched in the health-related databases
of Ovid MEDLINE, Ovid Embase, The Cochrane Library,
and Google Scholar. The search strategies for the Ovid
MEDLINE are given in Additional file 1. Our search was
restricted to publications in the English language up to
February 2018. To identify ongoing or completed tri-
als, we also searched in ClinicalTrials.gov (http://
www.clinicaltrials.gov/), WHO International Clinical
Trials Registry Platform (http://apps.who.int/trial-
search/Default.aspx) and EU Clinical Trials Register
(https://www.clinicaltrialsregister.eu/). We did not
search for the adverse effects of antiviral drug inter-
ventions separately and only used data contained in
the publications identified for the present study.
Study selection
Individual studies were selected based on the PICOS format
[13]:
Study Population (P)
Patients co-infected with HBV and HIV, regardless of
gender, age, the severity of infections and HBV genotype
were included.
Interventions (I)
Antiviral drugs (monotherapy or combination treatment)
for the treatment of HBV infection were considered.
Comparisons (C)
Data from an antiviral drug versus an alternative antiviral
drug, combination treatment, or placebo were included.
Study Outcomes (O)
Treatment success (virologic response) was defined as
achieving undetectable levels of HBV DNA in patients at
the end of 1 year (36–52 weeks). This represents the
suppression of HBV DNA levels as stated in the primary
studies on the scheduled follow-up, regardless of their
HBeAg status. Adverse events /serious adverse events
were as stated in the included studies. For example, hep-
atic failure after the commencement of therapy was de-
fined as an increase in ALT to > 3-5x the upper limit of
normal from a baseline value below this level [14, 15].
Study design (S)
RCT.
Studies which did not meet the inclusion criteria were
excluded.
Data extraction
Two review authors independently screened the titles
and abstracts of citations from the electronic database
search and retrieved full-text of all potentially relevant
articles. When studies had duplicate publications, we ex-
tracted the maximum amount of data from the available
publications. The two review authors then independently
checked the full-text articles for eligibility based on the
inclusion criteria. The two reviewers extracted data from
the included studies using a piloted data extraction
sheet. Data collected were authors, country, publication
year, participant’s characteristics, details of intervention
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and controls regimen (dosage, route of administration,
frequency and duration), outcomes, method of outcome
measurements, follow-up time points of the outcome
and adverse events. Any discrepancy between the two
investigators was resolved by discussion and consensus.
Methodological quality assessment
The methodological quality of the included trials was evalu-
ated, using the Cochrane risk of bias tool [16]. We checked
three domains for the risk of bias assessment such as ad-
equate sequence generation, allocation concealment, blind-
ing of participants and outcome assessors for each trial for
the virologic response. As there was only one outcome in
the current review, the risk of bias assessments at the out-
come level was applied to the whole study. We used these
ratings to further Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) assessment
for risk of bias category accordingly [17].
Data synthesis
Main outcome in this review was success of treatment
by HBV antiviral treatment as determined by virologic
response. The intention-to-treat (ITT) analysis was used
for efficacy assessments.
Pairwise comparison
If the studies included had been reported in similar ways (i.e.
the comparators, the outcomes reported and follow-up time
point), then direct pairwise meta-analyses of head-to-head
comparisons were performed using standard frequentist ap-
proaches. We used odds ratio (OR) along with 95%confi-
dence interval (CI) for the dichotomous variable as a
measure of the strength of association between the treatment
used and efficacy/adverse events. We pooled ORs with a
DerSimonian-Laird random-effects model, as the heterogen-
eity was high (I2 > 50%) [13]. Initially, we planned to perform
a sensitivity analysis to investigate the potential impact of
studies at high risk of bias in the pooled studies. We also
planned to do stratified analysis by prior LMV naive or LMV
experienced. However, the number of studies identified was
too small to carry out these analyses. Publication bias was
not assessed with the contoured-enhanced funnel plot be-
cause the number of included studies was fewer than the rec-
ommended 10 included studies [13]. We assumed the risk of
Fig. 1 Study selection PRISMA flowchart
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publication bias may be higher as the estimates were based
on small RCTs [18].
Network meta-analyses
We performed network meta-analyses within a frequen-
tist framework using random-effects models [10, 19, 20].
The approach incorporated both direct and indirect in-
formation through the use of a common comparator to
obtain estimates of the relative interventional effects on
multiple intervention comparisons. We established net-
work connections. The percentage contribution of each
estimate to the entire network was calculated. The re-
sults were presented as contribution plots in which the
weighted squares indicated the percentage contribution
of each comparison [21].
We investigated network inconsistency with the use of
the global Wald test for inconsistency [22]. The network
meta-analysis results were reported for ‘mixed treatment
contrasts’, including both direct and indirect evidence
from across the entire network [21, 22]. For a ranking of
the effectiveness and the uncertainty, probability values
were summarised and reported as ‘Surface Under the
Cumulative Ranking Curve’ (SUCRA), as described else-
where [11, 19]. SUCRA = 1 or 0, if an antiviral drug
intervention ranked first or last, respectively. Statistical
significance was set at p value ≤0.05.
Assessing the quality of evidence
We assessed the quality of evidence derived from the
pairwise and network meta- analysis, following the
Table 1 Characteristics of the studies included in the network meta-analysis
Study
[Reference No]
Country RCT
design
Total
samples
Age in year
(SD or range)
Males Comparators Time point
in week
Diagnosis
of HBV
Main mode
of transmission
Remarks
Dore, 1999
[14]
Canada,
Australia,
Europe, &
South Africa
(CAESAR)
2 arms;
ITT
122 37a
(range: 22–70)
96% LMV
(150 mg
twice/D) vs
placebo
4, 8, 12,
20, 28, 36,
44, 52.
Amplicor
PCR
(Roche, NJ)
68% ART
received
Dore, 2004
[25]
Western EU,
North
America,
Australia
2 arms;
as treated
Gr 1: 12
Gr2:11
Gr 1: 40a
Gr2:42a
100%a Gr1: TDF
(300 mg/D)
vs placebo.
Gr 2:TDF
(300 mg/D)
vs TDF + LMV
(150 mg
twice/D).
12,24,48 HBV DNA
(Roche
Amplicor),
A sub-study
of 908 ART
exp. (Gr1) &
903 naive
(Gr2); ART
naïve group
& ART
experienced
group
Peters, 2006
[26]
USA 2 arms;
ITT
52 47a 24% ADV vs TDF 12,24,36,48 Roche
Amplicor
CobasPCR
IVDU:13.5% stop early
after interim
results
Mathews,
2008 [27]
3 countries;
Netherlands,
Australia &
Thailand (NAT)
3 arms;
ITT
36 35.5 (SD:±8.4) 64% LMV
(150 mg
twice/D);
TDF
(300 mg/D)
12,24,48 Versant HBV
DNA 3.0
bDNA assay
(Bayer
HealthCare, NY);
COBAS
TaqMan
HBV Test
(Roche
Diagnostics NJ).
Hetero (78%) ART naiïve;
EFV
(600 mg/D)
to all 3 groups;
7 (19%)
with AIDS
Avihingsanon,
2010 [15]
Thailand 2 arms;
ITT
16 34a
(range: 30–39)
12% TDF + FTC
(600 mg +
300 mg/D)
vs FTC
(300 mg/D)
12,24,48 Versant HBV DNA
3.0 bDNA assay
(Bayer
HealthCare, NY);
COBAS TaqMan
HBV Test (Roche
Diagnostics NJ).
Hetero (75%) EFV (600 mg
single dose/D)
Gu, 2014 [28] China 2 arms;
ITT
50 36 (SD:±9.5) 88% TDF+ LMV
vs LMP
12,48,96 COBAS
Ampliprep/
COBAS TaqMan
86% hetro +
homo: 51.2%
MSM
ART received
Wang,
2016 [29]
China 2 arms;
ITT
80 29a
(range: 24–36)
0% TDF + LMV
vs LMV
36 m2000 RT
System (Abbott
RT HBV Assay,
California),
_ pregnant
women
ART antiretroviral therapy, D day, exp. experienced, hetro hetrosexuial contacts, homo homosexual contacts, ITT intention-to-treat analysis, IVDU
intravenous drug users, MSM men who have sex with men, RT RealTime, SD standard deviation, SVR suppression of viral loads, yr. year; amedium;
$$median value (range or IRQ values are not provided)
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GRADE approach described elsewhere [17, 20, 23, 24].
We rated direct evidence from RCTs, using the standard
GRADE approach on the five categories such as study
limitations (risk of bias), precision, consistency of re-
sults, directness of evidence and publication bias. On
these five categories, we judged the overall confidence in
estimates of effect for virologic responses for each direct
comparison as ‘high’, ‘moderate’, ‘low’ or ‘very low’ quality
of evidence. For indirect comparison, we rated evidence
from the most dominant first-order loop by first taking
the lowest certainty of direct comparisons. We consid-
ered further rating down, if there were concerns with
intransivity [24]. For NMA mixed estimates, we started
with the higher quality of the two certainty ratings and
rated down certainty for incoherence (degree of incon-
sistency between direct and indirect effect estimates) in
the final quality rating [23, 24]. We did not rate down
intransivirty [11] in the current study as there was no
important imbalance in the distribution of effect modi-
fiers (e.g. age, gender, dosage) across seven studies. Pair-
wise meta-analysis was done with RevMan 5.3 (The
Nordic Cochrane Centre, The Cochrane Collaboration),
while network meta-analysis was with STATA 15.0
(StataCorp, TX).
Results
Trials included
Figure 1 shows a four-phase study selection process. The
initial search yielded 1171 citations. After the title and
abstract screening, 25 full-text papers were reviewed and
a final of 7 studies (n = 329) were included in this review
[14, 15, 25–29]. The largest comparison was LMV versus
placebo (n = 122, 32.4%), followed by LMV versus TDF
plus LMV (n = 116, 31%). A summary of the 18 excluded
studies [2, 6, 7, 30–44] is provided in Additional file 2:
Table 1 presents the characteristics of the included studies.
The number of participants ranged from 12 [25] to 122
[14]. Three RCTs were multi-country studies [14, 25, 27],
two RCTs were from China [28, 29] and one RCT each was
from Thailand [15] and the USA [26]. Six studies were
two-arm RCTs [14, 15, 25, 26, 28, 29], and only one study
was a three-arm RCT [27]. The distribution of studies and
comparisons are presented in Additional file 3. The risk of
bias was affected by inadequate information on the alloca-
tion concealment and the blinding status of the RCTs in-
cluded (Additional file 4).
Six-node analysis
Figure 2 shows a network geometry of treatment success
and provides eight direct (n = 329) and seven indirect com-
parisons for six treatment options. Six treatment options
included were five antiviral drugs such as adefovir dipivoxil
(ADV), FTC, LMV, TDF, TDF plus LMV and placebo. The
contributing plot indicates the contribution of each direct
comparison to indirect and network estimates (Fig 3). The
weighted percentage contributions of each comparison
were distributed fairly equally in the entire network of evi-
dence. The global Wald test suggested the presence of
consistency in the network [Chi2 (4) = 3.63, p = 0.46].
Pairwise analysis of the relative efficacy of antiviral for
viral suppression in HBV/HIV was reported from eight
pairwise comparisons. The result is very low certainty of
evidence that there were no differences between the
treatment regimens in virologic response and wide
95%CIs, which spanned both benefit and harm (Fig 4).
Fig. 2 Network map of different antiviral drugs for treating hepatitis B and HIV co-infected patients
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For instance, four studies compared LMV with TDF plus
LMV. There was no difference between the two regi-
mens in virologic response (LMV vs TDF plus LMV (OR
0.37, 95%CI: 0.06–2.41; 218 fewer (121 more to 602
fewer) per 1000 patients, very low certainty). A single
trial reported no difference between FTC and TDF in vi-
rologic response for the co-infected patients (FTC vs
TDF (OR 0.07, 95%CI: 0.00–1.14; 166 more (199 more
to 310 fewer) per 1000 patients, very low certainty]
(Table 2). The direct, indirect and network (mixed) com-
parisons for the six-node comparison after completing
assessment for GRADE criteria are presented in Tables 2,
3 and Fig 5.
Treatment relative ranking in the network meta-analysis
is presented in Additional file 5. FTC had the highest
probability of being the best choice for treating patients
co-infected with HBV/HIV, with the TDF plus LMV com-
bination being the second best. The SUCRA and ranking
results are under the circumstances of small number of
the included studies and wide estimates ranging from
benefit to harm. The evidence on which the SUCRA rank-
ings are warranted was of very low quality and therefore
untrustworthy [45]. We made overall evidence in view of
the GRADE approach rather than the SUCRA rankings
(Fig 5).
Overall, there was very low certainty evidence whether
any antiviral regimens included in this study were better
in virologic response for treatment of HBV/HIV co-in-
fected patients since the certainty of the evidence was
assessed as very low.
Other outcomes
Due to the small number of studies, other outcomes lim-
ited the summary estimates. Two studies had reported
that HBV DNA was significantly decreased after treat-
ment [14, 28]. With regards to the adverse events/ser-
ious adverse events, three studies included in this review
had reported hepatic flare or ALT flare after initiation of
antiviral treatments. Due to variations in antiviral drugs
administered and/or inconsistences in reporting, it was
Fig. 3 Contributing plot
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difficult to make the pooled analysis. The prevalence of
hepatic flare after initiation of antiviral treatments was
54.5% (6/11) [25], while this was 21.2% (11/52) in one
trial [26] and 19% (3/16) in another trial [15]. These
events were resolved, and none was associated with the
development of hepatic decomposition [15, 25, 26].
Discussion
Summary of main results
In this network meta-analysis, we have combined direct
and indirect evidence on the relative efficacy of antiviral
drugs interventions at the end of maximum 1 year treat-
ment. The results of this NMA provide very low quality
evidence that no regimen provided better rates of treat-
ment success.
The use of virologic responses to represent suppres-
sion of HBV DNA after giving antiviral treatments
served as surrogate outcomes in this review was clinic-
ally relevant. The main goal of the treatment of HBV in-
fection was the sustained suppression of HBV
replication because suppression is associated with a
normalization of transaminase levels and improvement
in histologic findings [6, 8].
There was only one study evaluating the efficacy of
FTC and showed no difference in virologic response
than the comparators. Also, any regimen in the current
study was no different from the comparators and there
Fig. 4 Forest plot of pairwise meta-analysis
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were wide CIs. In the GRADE approach, it was rated
down two levels for imprecision. Overall, the evidence
was very low quality. Hence, the present findings were
limited in definitively resolving the question of optimal
treatment choice. Studies have reported that treatment
responses to TDF plus LMV combination therapy would
be likely to be mediated by TDF alone as LMV may have
no or minimal antiviral efficacy in the presence of
LMV-resistant HBV mutants [46]. A study had reported
that TDF monotherapy could maintain effective viral
suppression over up to 288 weeks of continuous therapy
without the selection of TDF resistance [47]. The fact
that the LMV monotherapy was ranked higher than the
TDF monotherapy as found in this review was an unex-
pected outcome and this was very low certainty of evi-
dence. Studies have reported that 3TC (LMV) resistant
HBV emerged in about 40 and 90% of patients after 2
and 4 years on 3TC respectively [48], while TDF had a
high resistance barrier with no resistance identified to
date after up to 6 years of monotherapy for chronic
hepatitis B [49]. A systematic review had highlighted
that entecavir and TDF were most effective in HBeAg-
positive treatment-naive patients, while TDF was most
effective in HBeAg negative treatment-naive patients in
Table 2 GRADE quality assessment of direct evidence of each pairwise treatment comparison for treatment success
Treatment
comparison
Number of
head-to head
trials(n)
Study
limitations`
Precision Consistency Directness Publication
bias
Direct Estimate;
OR (95% CI)
Absolute effect per
100 treated (95% CI)
Overall
quality of
evidence
LMV vs TDF
plus LMV
4 (158) seriousa very seriousb very serious
(I2: 62%)c
serious likely to exist 0.37
(0.06–2.41)
218 fewer
(from 121 more
to 602 fewer)
very low
⊕◯◯◯
FTC vs TDF 1 (15) seriousa very seriousa not serious not serious likely to exist 0.07
(0.00–1.14)
513 fewer
(0 to 11 more)
very low
⊕◯◯◯
LMV vs TDF 2 (84) seriousa very seriousa very seriousc
(I2: 78%)
serious likely to exist 0.12
(0.00–5.71)
27 fewer (87 fewer
to 141 more)
very low
⊕◯◯◯
LMV vs
placebo
2 (130) seriousa very seriousa not serious
(I2: 0%)
serious likely to exist 0.73
(0.2–2.69)
432 fewer
(0 to 109 more)
very low
⊕◯◯◯
TDF vs TDF
plus LMV
2 (37) seriousa very seriousa very seriousc
(I2: 51%)
serious likely to exist 1.21 (0.06–
23.06)
21 more (127 more
to 586 fewer)
very low
⊕◯◯◯
TDF vs
placebo
1 (12) seriousa very seriousb not serious not serious likely to exist 105.00
(1.65–6697.38)
0 fewer (0 fewer
to 0 fewer)
very low
⊕◯◯◯
TDF plus LMV
vs placebo
1 (15) seriousa very seriousb not serious not serious likely to exist 7.00
(0.24–206.78)
239 more (294
more to 341 fewer)
very low
⊕◯◯◯
ADV vs TDF 1 (52) seriousa very seriousb not serious not serious likely to exist 3.23
(0.85–12.35)
212 more (19 fewer
to 534 more)
very low
⊕◯◯◯
For domains “Study Limitations”, “Precision”, “Consistency”, and “Directness”: rated as not serious, serious, or very serious issues. For the domain “Publication bias”:
not likely or likely to exist. Reasons are provided when rating down. All direct comparisons begin with a “High” rating. aRated down one level for risk of bias as
study limitations;bRated down two levels for imprecision; cRated down two levels for substantial heterogeneity based on I2 values; CI Confidence interval, OR Odds
ratio. ADV Adefovir, FTC Emtricitabine, LMV Lamivudine, TDF Tenofovir disoproxil fumarate, TDF plus LMV Combined Tenofovir disoproxil fumarate and Lamivudine
Table 3 Network estimates of treatment success with 95% confidence intervals and GRADE assessments
Treatment
comparison
Direct estimate; OR
(95% CI)
quality of
evidence
Indirect estimate; OR
(95% CI)
quality of
evidence
Network estimate; OR
(95% CI)
quality of
evidence
ADV FTC Not available Not available 0.02 (0.00–3.01) Very low ⊕◯◯◯ 0.02 (0.00–3.01) Very low ⊕◯◯◯
ADV vs LMV Not available Not available 0.07 (0.00–3.36) Very low ⊕◯◯◯ 0.07 (0.00–3.36) Very low ⊕◯◯◯
ADV vs TD Not available Not available 0.31 (0.02–6.28) Very low ⊕◯◯◯ 0.31 (0.02–6.28) Very low
⊕◯◯◯S
ADV vs TDF
plus LMV
Not available Not available 0.18 (0.00–9.2) Very low ⊕◯◯◯ 0.18 (0.00–9.2) Very low ⊕◯◯◯
ADV vs placebo Not available Not available 0.05 (0.00–4.71) Very low⊕◯◯◯ 0.05 (0.00–4.71) Very low ⊕◯◯◯
FTC vs LMV Not available Not available 3.01 (0.03–287.25) Very low ⊕◯◯◯ 3.01 (0.03–287.25) Very low ⊕◯◯◯
FTC vs TDF
plus LMV
Not available Not available 7.82 (0.08–778.9) Very low 7.82 (0.08–778.9) Very low
FTC vs placebo Not available Not available 2.23 (0.01–370.4) Very low ⊕◯◯◯ 2.23 (0.01–370.4) Very low ⊕◯◯◯
ADV Adefovir, FTC Emtricitabine, LMV Lamivudine, TDF Tenofovir disoproxil fumarate, TDF plus LMV Combined Tenofovir disoproxil fumarate and Lamivudine.
Rated down one level for incoherence
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all surrogates outcomes at the end of first year of
therapy [50].
In published reviews, TDF demonstrated the most
effective viral treatment for patients with chronic HBV
[50, 51]. This was not observed in this study on patients
with dual HBV/HIV infection. This implied that TDF is
less potent for suppression of HIV DNA. A concern is that
suppression of HBV DNA to undetectable levels was de-
termined in the study population with continuing antiviral
therapy. Hence, the stability of treatment response, after
stopping therapy has not yet been investigated.
Study limitations
Due to a small number of studies included in this review
for direct comparison, there was inadequate statistical
power to detect significant differences among the drugs
evaluated. Moreover, the currently recommended limit
of serum HBV-DNA diagnostic assays is 20 IU/ml or
10 IU/ml (around 100 copies/ml or 50 copies/ml) on the
scheduled follow-up regardless of their HBeAg status.
The studies included in this analysis used different
threshold for the definition of virological suppression.
For instance, it was a serum HBV-DNA < 1000 copies/
ml in one study [25], while other studies used < 400 cop-
ies/ml [14] or < 200 copies/ml [26]. Due to the use of
higher cut-off for quantification of serum HBV-DNA
diagnostic assays in the primary studies, the misclassifi-
cation bias is a concern. An interpretation of the find-
ings, therefore, needs a caution regarding such bias.
Studies in non-English language may have been missed.
Telbivudine is licensed for HBV and HIV treatment, but
none of the included studies assessed this antiviral drug. As
our focus was on clinical effectiveness only, the cost-effect-
iveness of preferentially using a particular drug intervention
was not done and should be examined in future studies.
The highest prevalence was observed in sub-Saharan Africa
and East Asia, where 5–10% of the adult population was
chronically infected with HBV [52, 53]. But, none of the
RCTs were from sub-Saharan Africa, indicating a geograph-
ical imbalance and an interpretation of this review was lim-
ited with regard to generalizability. Available data was
sufficient to summarize only one surrogate clinical outcome.
Currently, there is no agreement on the most appropriate
surrogate markers of a long-term outcome or even of the
validity of on-treatment measurements [49].
Nevertheless, the outcome used in this review was rea-
sonable; studies have shown that for treatment with
LMV, telbivudine, and ADV, subsequent resistance is
low for those whose viral load is maintained at less than
1000 copies/m [54].
Clinical implications
The escalating HIV burden in some countries with a
background prevalence of chronic HBV infection will
contribute to an increasing number of people with
HIV-1/HBV co-infection in the affected countries. Thus,
an antiviral agent with dual efficacy against HIV-1/HBV
in combination with at least one other antiretroviral
agent could provide a cost-effective approach to manage
these two chronic viral infections in resource-limited
countries [14].
Conclusion
The findings suggest that there was insufficient evi-
dence to provide the relative effectiveness of currently
available antiviral drugs with dual activity in treating
co-infection of HBV/HIV. Future well-designed, large
clinical trials in this field to address other important
outcomes from different geographical settings are
recommended.
Fig. 5 Results of pairwise meta-analyses and network meta-analysis with consistency model for antiviral treatment
Naing et al. BMC Infectious Diseases          (2018) 18:564 Page 9 of 11
Additional files
Additional file 1: Citations and Ovid MEDLINE. (DOC 44 kb)
Additional file 2: Excluded studies and reasons for exclusion. (DOC 38 kb)
Additional file 3: Distribution of studies and comparisons. (DOC 40 kb)
Additional file 4: Risk of bias assessment by the review authors. (DOC 33 kb)
Additional file 5: Treatment relative ranking. (DOC 31 kb)
Abbreviations
ADV: Adefovir; ART: Antiretroviral therapy; CENTRAL: Cochrane Central
Register of Controlled Trials; CI: Confidence interval; FTC: Emtricitabine;
GRADE: Grading of Recommendations Assessment, Development, and
Evaluation; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus;
HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus;
LMV: Lamivudine; NMA: Network meta-analysis; OR: Odds ratio; PRISMA-
NMA: PRISMA Extension Statement for Reporting of Systematic Reviews
Incorporating Network Meta-analyses of Health Care Interventions;
RCT: Randomized trials; SUCRA: Surface under the cumulative ranking curve;
TDF: Tenofovir disoproxil fumarate
Acknowledgements
The authors thank the patients and researchers of the primary studies. We
are grateful to the editors and reviewers for their comments and helpful
inputs. We thank our institutions for allowing us to perform this study. We
thank Professor Frederick Smales and Dr. Sompong Vongpunsawad for input
in the revised manuscripts. YP obtained the Research Chair Grant (NSTDA).
Funding
This work was supported by funding from the International Medical
University (IMU), Malaysia [ID 351–2016]. The contents are the sole
responsibility of the study authors and do not necessarily reflect the views of
IMU. The funding agencies had no role in the study design, data collection
or analysis, manuscript writing, or the decision to submit for publication.
Availability of data and materials
The data supporting the findings can be found in the main paper and an
additional file.
Authors’ contributions
KST: conceptualized, participated in its design, interpreted the results and
helped to draft the manuscript, YP: participated in its design, collected data,
interpreted the results and helped to draft the manuscript. CN: designed,
collected data, carried out the statistical analysis, wrote the first draft and
revised the manuscript together with YP and KST. All authors read and
approved the final version for submission.
Ethics approval and consent to participate
The need for approval was waived as this study solely used published
human data.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1International Medical University, Kuala Lumpur, Malaysia. 2Division of
Tropical Heath and Medicine, James Cook University, Townsville, QLD,
Australia. 3Centre of Excellence in Clinical Virology, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand.
Received: 24 April 2018 Accepted: 5 November 2018
References
1. Hilleman MR. Comparative biology and pathogenesis of AIDS and hepatitis
B viruses: related but different. AIDS Res Hum Retrovir. 1994;10:1409–19.
2. Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related
mortality in the multicenter AIDS cohort study (MACS). Lancet. 2002;360:
1921–6.
3. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et
al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly
active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS. 2005;19:593–601.
4. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol.
2006;44(1 Suppl):S6–9.
5. Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the
selection of drug resistance in HIV and hepatitis B and C viruses? J
Antimicrob Chemother. 2008;62:1–4.
6. Thio CL. Hepatitis B and human immunodeficiency virus coinfection.
Hepatology. 2009;49.
7. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ.
2004;329(7474):1080–6.
8. Benhamou Y, et al. Safety and efficacy of adefovir dipivoxil in patients co-
infected with HIV-1 and lamivudine-resistant hepatitis B virus:an open-label
pilot study. Lancet. 2001;358:718–23.
9. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in Adults and
Adolescents Living with HIV. https://aidsinfo.nih.gov/guidelines/html/1/
adult-and-adolescent-arv-guidelines/25/hbv-hiv Accessed 23 May 2018.
10. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical
summaries for presenting results from multiple-treatment meta-analysis: an
overview and tutorial. J Clin Epidemiol. 2011;64:163–71.
11. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-
treatments meta-analysis: many names, many benefits, many concerns for the
next generation evidence synthesis tool. Res Synth Methods. 2012;3:80–97.
12. Cornell JE. The PRISMA extension for network meta-analysis: bringing clarity
and guidance to the reporting of systematic reviews incorporating network
meta-analyses. Ann Intern Med. 2015;162:797–8.
13. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. www.cochrane-handbook.org. Accessed 9 Mar 2018.
14. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M, et al. Dual efficacy
of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-
coinfected persons in a randomized, controlled study (CAESAR). The CAESAR
Coordinating Committee. J Infect Dis. 1999;180:607–13.
15. Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napisianant N, et al.
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with
emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Antivir Ther. 2010;15:917–22.
16. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al.
Cochrane Bias methods group; Cochrane Statistical Methods Group The
Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
BMJ. 2011;343:d5928.
17. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schünemann HJ, for the GRADE working group. GRADE: an emerging
consensus on rating quality of evidence and strength of recommendations.
BMJ. 2008;336:924–6.
18. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the
quality of evidence--publication bias. J Clin Epidemiol. 2011;64:1277–82.
19. Shim S, Yoon B-H, Shin I-S, Bae J-M. Network meta-analysis: application and
practice using Stata. Epidemiology and Health. 2017;39:e2017047.
20. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating
the quality of evidence. J Clin Epidemiol. 2011;64:401–6.
21. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools
for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.
22. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in
network meta-analysis: model estimation using multivariate meta-
regression. Res Synth Methods. 2012;3:111–25.
23. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa
TA, Rochwerg B, GRADE Working Group. Advances in the GRADE approach
to rate the certainty in estimates from a network meta-analysis. J Clin
Epidemiol. 2018;93:36–44 [Corrigendum to “Advances in the GRADE
Naing et al. BMC Infectious Diseases          (2018) 18:564 Page 10 of 11
approach to rate the certainty in estimates from a network meta-analysis” [J
Clin Epidemiol 2018;93:36–44].
24. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the
quality of evidence from a network meta-analysis. PLoS One. 2014;9(7):e99682.
25. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al.
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and –
experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect
Dis. 2004;189:1185–92.
26. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al.
Randomized controlled study of tenofovir and adefovir in chronic hepatitis
B virus and HIV infection: ACTG A5127. Hepatology. 2006;44:1110–6.
27. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat
R, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV
coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48:
1062–9.
28. Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, et al. Emergence of lamivudine-
resistant hbv during antiretroviral therapy including lamivudine for patients
coinfected with HIV and HBV in China. PLoS One. 2015;10:e0134539.
29. Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, et al. Hepatitis B virus
(HBV) load response to 2 antiviral regimens, tenofovir/lamivudine and
lamivudine, in HIV/HBV-coinfected pregnant women in Guangxi, China: the
Tenofovir in pregnancy (TiP) study. J Infect Dis. 2016;214:1695–9.
30. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson
RE, et al. Hepatitis B virus infection and response to antiretroviral therapy
(ART) in a south African ART program. Clin Infect Dis. 2008;47:1479–85.
31. Gutierrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, et al. Tenofovir-
based rescue therapy for advanced liver disease in 6 patients coinfected
with HIV and hepatitis B virus and receiving lamivudine. Clin Infect Dis.
2008;46:e28–30.
32. Lacombe K, Gozlan J, Boyd A, Boelle PY, Bonnard P, Malean JM, et al.
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B
virus in HIVHBV-coinfected patients. Antivir Ther. 2008;13:705–13.
33. Nuesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W,
et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in
patients with HIV/hepatitis B virus co-infection. AIDS. 2008;22:152–4.
34. Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir disoproxil
fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Med. 2009;
10:269–73.
35. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact
of hepatitis B virus infection on human immunodeficiency virus response to
antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49:1268–73.
36. Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic outcome of using
tenofovir/emtricitabine to treat hepatitis b in hiv-coinfected patients. ISRN
Gastroenterol. 2011;405390.
37. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G, et al. Impact
of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis
B virus individuals in a randomized clinical trial of antiretroviral therapy in
southern Africa. AIDS. 2011;25:1727–35.
38. Nelson M, Amaya G, Clumeck N, da Cunha CA, Jayaweera D, Junod P, et al.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients
with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III
randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother.
2012;67:2020–8.
39. Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Petcharapirat P,
et al. Quantitative HBsAg and HBeAg predict hepatitis b seroconversion
after initiation of HAARTt in HIV-HBV coinfected individuals. PLoS One. 2013;
8(4):e61297.
40. Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, et al.
Virologic and serologic outcomes of mono versus dual HBV therapy and
characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune
Defic Syndr. 2014;66:172–80.
41. Miailhes P, Maynard-Muet M, Lebossé F, Carrat F, Bouix C, Lascoux-Combe
C, et al. Role of a 48-week pegylated interferon therapy in hepatitis B e
antigen positive HIV-co-infected patients on cART including tenofovir:
EMVIPEG study. J Hepatol. 2014;61:761–9.
42. Yu S, Zhou Q, Zhao XM, Yuan M, Wang CT, Cheng XG, et al. Comparison of the
antiviral effects of different nucleos(t)ide analogues in chinese patients with
chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol. 2014;20:350–5.
43. Lee T, Núnez M. Longer duration of HBV-active antiretroviral therapy is
linked to favorable virological outcome in HIV-HBV co-infected patients. HIV
Clin Trials. 2009;10:153–9.
44. Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, et al. Lamivudine monotherapy-
based cart is efficacious for HBV treatment in hiv/HBV coinfection when
baseline HBV DNA <20,000 IU/mL. J Acquir Immune Defic Syndr. 2016;72:
39–45.
45. Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W,
Thabane L, et al. Approaches to interpreting and choosing the best
treatments in network meta-analyses. Systematic Reviews. 2017;6:79.
46. Lim Y-S. Management of Antiviral Resistance in chronic hepatitis B. Gut and
Liver. 2017;11:189–95.
47. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No
detectable resistance to tenofovir disoproxil fumarate after 6 years of
therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–42.
48. AIDSinfo. Considerations for antiretroviral use in patients with coinfections.
In: guidelines for the use of antiretroviral agents in HIV-1-infected adults
and adolescents http://aidsinfo.nih.gov/guidelines Accessed 2 Apr 2018.
49. Heathcote J, Gane EJ, deMan RA, Sing C, Sievert W, Mauss S, et al. Two year
tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV)
switch data en HBeAg-positive patients with chronic hepatitis B (Study 103),
preliminary analysis. Hepatology. 2008;48:376A.
50. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, et al. Tenofovir
and entecavir are the most effective antiviral agents for chronic hepatitis B:
a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;
139:1218–29.
51. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al.
Suppression of HBV by tenofovir in HBV/HIV Coinfected patients: a
systematic review and meta-analysis. PLoS One. 2010;8:e68152.
52. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide
prevalence of chronic hepatitis B virus infection: a systematic review of data
published between 1965 and 2013. Lancet. 2015;386:1546–55.
53. World Health Organization. Hepatitis B. Geneva: WHO; 2017. http://www.
who.int/mediacentre/factsheets/fs204/en/ Accessed 23 May 2018.
54. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic
response in hepatitis B and C. J Hepatol. 2008;49:634–51.
Naing et al. BMC Infectious Diseases          (2018) 18:564 Page 11 of 11
